Pharsight

Januvia patents expiration

JANUVIA's oppositions filed in EPO
JANUVIA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 8 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 8 months ago)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 2 months ago)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 2 months ago)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(3 years from now)

Januvia is owned by Merck Sharp Dohme.

Januvia contains Sitagliptin Phosphate.

Januvia has a total of 6 drug patents out of which 4 drug patents have expired.

Expired drug patents of Januvia are:

  • US7125873
  • US6699871*PED
  • US7125873*PED
  • US6699871

Januvia was authorised for market use on 16 October, 2006.

Januvia is available in tablet;oral dosage forms.

Januvia can be used as method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.

The generics of Januvia are possible to be released after 24 May, 2027.

Drug Exclusivity Drug Exclusivity Expiration
M (M) Dec 4, 2023
Pediatric Exclusivity (PED) Jun 4, 2024

Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 16 October, 2006

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist; Method of treating type 2 diabetes mellitus by administering ...

Dosage: TABLET;ORAL

How can I launch a generic of JANUVIA before it's drug patent expiration?
More Information on Dosage

JANUVIA family patents

Family Patents